CYP3A4 inducers might enhance the formation in the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Intently check clients taking ifosfamide with CYP3A4 inducers for toxicities and consider dose adjustment.
Individuals stabilized on corticosteroid therapy may demand dosage adjustments if barbiturates are additional to or withdrawn from their dosage program resulting from induction of hepatic microsomal enzymes by barbiturates
pentobarbital will lessen the level or outcome of almotriptan by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will decrease the extent or influence of piroxicam by influencing hepatic enzyme CYP2C9/ten metabolism. Insignificant/Importance Not known.
pentobarbital will decrease the extent or outcome of tolterodine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
pentobarbital will decrease the level or outcome of vincristine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Importance Unidentified.
fentanyl transdermal and pentobarbital both increase sedation. Keep away from or Use Alternate Drug. Restrict use to individuals for whom choice treatment possibilities are insufficient
pentobarbital will reduce the level or influence of nimodipine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Unknown.
pentobarbital will decrease the level or impact of irinotecan liposomal by impacting hepatic/intestinal enzyme CYP3A4 metabolism. more info Use Warning/Check.
Repeatedly watch critical signals throughout sedation and recovery period if coadministered. Cautiously titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
pentobarbital will lower the extent or outcome of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lower the extent or effect of bedaquiline by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Prevent or Use Alternate Drug. Avoid coadministration of bedaquiline with robust CYP3A4 inducers as a consequence of possible for lowered therapeutic outcome
pentobarbital will reduce the extent or impact of quinidine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
Reserve concomitant prescribing of those drugs in clients for whom other cure choices are inadequate. Limit dosages and durations for the minimal needed. Keep track of carefully for indications of respiratory depression and sedation.